The latest articles from BioStock
» Immunovia's sector colleague acquired for $8B
» Abliva raises awareness of mitochondrial diseases
» BioStock Studio: Scandion Oncology has appointed a new CEO
» 2cureX launches IndiTreat
» Study results support BrainCool's treatment for oral mucositis
» BioStock Studio: Redsense Medical's journey has begun
Read BioStock's latest for week 38 here.
Follow BioStock Live w/ Prostatype Genomics Wednesday, September 23, starting at 14 p.m. See the event here.
GPX Medicals The offering was heavily oversubscribed – the entire offering was subscribed 475 percent. Trading in the shares is expected to commence on Nasdaq First North Growth Market on October 2, 2020. Read more.
Aqilion announces THANKS1 as the drug target (target protein) in the body that drug candidates are directed at in the internal development program Alnitak. Read more.
Paxman announces that Cancer Australia has updated its guidelines for the management of early breast cancer to now include scalp cooling in conjunction with chemotherapy to reduce the risk of hair loss. Paxman has so far installed over 160 scalp cooling systems at 91 clinics in Australia. Read more.
VibroSense Dynamics strengthens its presence with VibroSense Meter II in occupational health care and research in oncology. Read more.
Nextstim announces that Kuopio University Hospital initiates pilot study with Nexstim's NBT system for a new protocol for depression treatment. Read more.
AlzeCure Pharma announces that they are providing a scientific update on Alzheimer's disease and the project platform Alzstatin on September 30. Read more.
Merck and Pfizer reports that the results from the phase III study JAVELIN Bladder 100 showed that Bavencio (avelumab) significantly prolonged survival in advanced urothelial cancer – results published in The New England Journal of Medicine. Read more.
Attana appears in five new scientific articles. Read more.
Annexin Pharmaceuticals submits application for Phase I study in the Netherlands, which is the first human study with the company's drug candidate ANXV. Read more.
Dignity agreement is entered into with ION Solutions to easily provide DigniCap to members of ION Group Purchasing Organization (GPO). Read more.
News received since yesterday:
An article has been published in Austria about Glycorex Transplants product Glycosorb-ABO which has been successfully used in stem cell transplantation. Read more.
Cantargias The nomination committee has proposed a new board member. Read moreThe company also called an extraordinary general meeting. Read moreIn addition, Analysguiden has published an analysis of Cantargia: “Dancing with the Greats”. Read more.
XVIVO Perfusion announced that the company's CFO Christopher Rosenblad has been appointed COO. New CFO will be Christopher Nordstrom, XVIVO's current CFO. Read more.
Aegirbio has signed an agreement with Viraspec to conduct final testing of the company's Covid-19 testing product. Read more.
Orphazyme has introduced a new incentive program for the company's board members. Read moreIn addition, the company is initiating a global offering consisting of an initial public offering of ADSs in the United States and a simultaneous private placement of common shares in Europe. Read more.
Episurf Medical has now published a summary from the capital markets day that the company held in mid-September. Read more.
Genmab and Seattle Genetics presented data on ESMO Virtual Congress from its phase II study evaluating tisotumab vedotin against recurrent or metastatic cervical cancer. Read more.
The urology clinic at Kalmar County Hospital has organized the course "Transurethral Microwave Therapy", (TUMT), which is also the basic methodology in CoreTherm Concept, ProstaLunds method for treating benign prostatic hyperplasia. Read more.
SyntheticMRs software solution SyMRI has received regulatory approval in Saudi Arabia and Thailand. Read more.
Oncology Venture calls an extraordinary general meeting. Read more.
Novo Nordisk published information about its share repurchase program. Read more.
Integral has corrected a previous press release regarding the introduction of the company's OPRA Implant System of Memorial Hermann Orthopaedic and Spine Hospital, Texas. Read more.
This morning's winner: Paxman 12,75%, Episurf 12,74%, Zenicor 10,37%, Ascelia Pharma 8,96%, Oncology Venture 8,90%
This morning's losers: BrainCool -9,83%, Biotage -6,18%, Alzinova -5,06%, Scandion Oncology -4,49%, SensoDetect -4,26%
Index: OMXS30 1790,56 1,13%, Healthcare 0,68%
More articles from BioStock
» Ziccum could become a key player in vaccine manufacturing
» Saniona CEO: momentum for Tesomet in two rare diseases
» Umecrine Cognition's Phase II results led to prestigious presentation
» BioStock studio: Idogen's CEO comments on updated timelines
» Dicot reports positive study results for Libiguin